Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.45 |
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA9 | Q16790 | 8/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12094119 | 0.84 | LGALS3 (0.54) | FGF1FGF2VEGFAHPSEHRAS | |
| SCHEMBL12094113 | 0.84 | LGALS3 (0.54) | FGF1FGF2VEGFAHPSEHRAS | |
| SCHEMBL19036050 | 0.84 | LGALS3 (0.54) | FGF1FGF2VEGFAHPSEHRAS | |
| SCHEMBL31695082 | 0.84 | HRAS (0.48) | FGF1FGF2VEGFAHPSECA12 | |
| SCHEMBL18756738 | 0.81 | HTT (0.50) | LMNASMN1; SMN2LGALS8HTT | |
| SCHEMBL8985399 | 0.78 | TGM2 (0.49) | LMNASMN1; SMN2LGALS8HTT | |
| SCHEMBL28333071 | 0.77 | LMNA (0.54) | LMNASMN1; SMN2LGALS8HTT | |
| SCHEMBL13855545 | 0.76 | FGF1 (0.38) | FGF1FGF2VEGFAHPSECA12 | |
| SCHEMBL11435111 | 0.75 | HTT (0.50) | HTT | |
| SCHEMBL4969178 | 0.74 | HRAS (0.43) | FGF1FGF2VEGFAHPSEHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647613-B2 | Drug carrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20090136443-A1 | Drug Carrier | OXGENIX CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136443-A1 | Drug Carrier | ABCB11, SLC47A1, SLC47A2 | FGF1 1359/4885FGF2 665/4885VEGFA 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.